%0 Journal Article
%A Karpinski, Madeleine J
%A Hoberück, Sebastian
%A Fendler, Wolfgang P
%A Civan, Caner
%A Bundschuh, Ralph A
%A Thomas, Christian
%A Bjartell, Anders
%A Trägårdh, Elin
%A Soeterik, Timo F W
%A Evangelista, Laura
%A Vondrak, Andrej
%A Rasul, Sazan
%A Forner, Laura
%A Giorgio, Andrea Di
%A Scholtissek, Helen
%A Miksch, Jonathan
%A Holzgreve, Adrien
%A Lanfranchi, Francesco
%A Rahbar, Kambiz
%A Hofman, Michael S
%A Rauscher, Isabel
%A Güven, Osman
%A Eiber, Matthias
%A Ayati, Narjess
%A Umutlu, Lale
%A Herrmann, Ken
%A Hadaschik, Boris
%A Emmett, Louise
%T Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.
%J European urology
%V nn
%@ 0302-2838
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2025-02240
%P nn
%D 2025
%Z epub / brief report
%X The PRIMARY score was implemented in Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) version 2 to improve accuracy for the diagnosis of clinically significant prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography (PET). We reviewed overall survival (OS) for patients who underwent PSMA PET for initial staging to evaluate the prognostic value of PRIMARY in a large, international, multicenter cohort. The cohort comprised 1889 patients who underwent PSMA PET for initial staging of prostate cancer at investigator sites across Europe and Australia between 2012 and 2021. Hazard ratios (HRs) with 95
%K Overall survival (Other)
%K PRIMARY score (Other)
%K Positron emission tomography (Other)
%K Prostate cancer (Other)
%K Prostate-specific membrane antigen (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41168067
%R 10.1016/j.eururo.2025.10.013
%U https://inrepo02.dkfz.de/record/305581